Kennedy Capital Management Inc Position in Cambrex Corporation (NYSE:CBM) Lowered as Price Rose

May 16, 2018 - By Catherine Diaz

Big Money Sentiment decreased to 1.15 in 2017 Q4. It has change of 0.43, from 2017Q3’s 1.58. The ratio worsened due to CBM positioning: 33 sold and 71 reduced. 38 funds acquired stakes and 82 increased stakes. Investors holded 31.63 million in 2017Q3 but now own 32.02 million shares or 1.25% more. Two Sigma Securities Limited Co has 0.01% invested in Cambrex Corporation (NYSE:CBM). Deutsche Comml Bank Ag, a Germany-based fund reported 208,839 shs. Lsv Asset Mgmt holds 0% of its capital in Cambrex Corporation (NYSE:CBM) for 62,750 shs. 12,922 are owned by Stone Ridge Asset Mgmt Ltd Com. Alphaone Invest Service Lc holds 45,529 shs. Bancorp Of America De owns 233,782 shs. Aperio Limited Co holds 0% or 9,759 shs in its capital. Dimensional Fund Advsr L P reported 0.03% of its capital in Cambrex Corporation (NYSE:CBM). Brown Advisory, Maryland-based fund reported 895,240 shs. The California-based Lpl Fincl Ltd Limited Liability Company has invested 0% in Cambrex Corporation (NYSE:CBM). Mutual Of America Capital Management Ltd Liability Corp owns 25,489 shs. Portolan Management Limited Liability Company has invested 0.76% of its capital in Cambrex Corporation (NYSE:CBM). Moreover, Summit Creek Advsr Ltd Limited Liability Company has 0.97% invested in Cambrex Corporation (NYSE:CBM). Kennedy has invested 0.38% of its capital in Cambrex Corporation (NYSE:CBM). Moreover, D E Shaw & has 0.02% invested in Cambrex Corporation (NYSE:CBM).

CBM registered $5.33 million net activity with 0 insider purchases and 2 insider sales since May 7, 2018. $3.34M worth of stock was sold by SARGEN GREGORY on Monday, May 7.

Kennedy Capital Management Inc reduced its stake by 44.09% in Cambrex Corporation (NYSE:CBM), according to 2018Q1 Securities and Exchange filling. The company’s stock Popped Up 5.58% while Kennedy Capital Management Inc sold 193,214 shares. At the end of 2018Q1, the 244,994 shares of the major pharmaceuticals company held by the institutional investor were valued at $12.81M, down from 438,208 at the end of the previous reported quarter. Cambrex Corporation has $1.58B MC. Ticker’s shares touched $47.95 during the last trading session after 0.62% change.Currently Cambrex Corporation is uptrending after 2.87% change in last May 17, 2017. CBM has also 228,337 shares volume. The stock underperformed the S&P 500 by 8.68%.

For a total of 600,021 shares it increased its holding in Biotelemetry Inc (NASDAQ:BEAT) by 458,774 shares in the quarter, and has risen its stake in Pq Group Holdings Inc ().

Kennedy Capital Management Inc is a Missouri-based institutional investor with more than $5.67 billion AUM in March, 2014. Taken from Kennedy Capital Management latest Adv, the fund reported to have 50 full and part-time employees. Among which 31 performing investment advisory and research functions. The institutional investor had more than 500 clients.

Cambrex Corporation (NYSE:CBM) Ratings Coverage

A total of 2 analysts rate Cambrex Corp (NYSE:CBM) as follows: 1 “Buy”, 1 “Hold” and 0 “Sell”. Тherefore 50% are bullish. (NYSE:CBM) has 2 ratings reports on May 17, 2018 according to StockzIntelligence. On Wednesday, February 14 the company was downgraded by Longbow. On Tuesday, January 16 the rating was maintained by William Blair with “Buy”.

Cambrex Corporation, a life sciences company, provides various services and products for the development and commercialization of new and generic therapeutics worldwide.The firm is valued at $1.58 billion. The Company’s products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as other fine chemicals.The P/E ratio is 15.66. The firm serves generic drug companies; and companies that discover and commercialize small molecule human therapeutics.

Cambrex Corporation (NYSE:CBM) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: